Navigation Links
Neurocrine Biosciences Reports First Quarter 2013 Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2013.  For the first quarter of 2013, the Company reported net loss of $12.1 million, or $0.18 loss per share, compared to a net loss of $0.9 million, or $0.01 loss per share, for the same period in 2012. This $11.2 million change in operating results is primarily due to lower revenue recognized during 2013 under the Company's license agreements with AbbVie and Boehringer Ingelheim. The sponsored research and development segments of both of these agreements concluded, as scheduled, during 2012.

The Company's balance sheet at March 31, 2013 reflected total assets of $183.9 million, including cash, cash equivalents, investments and receivables of $176.9 million compared with balances at December 31, 2012 of $196.0 million and $188.3 million, respectively.  

"AbbVie has made great progress with elagolix. The initiation of this Phase IIb study in uterine fibroids is another significant milestone for this program," said Kevin Gorman , Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Our VMAT2 program also continues to move forward in two Phase IIb tardive dyskinesia studies, with an End of Phase II FDA meeting anticipated later this year."

Revenues for the first quarter of 2013 were $0.7 million compared with $11.3 million for the same period last year. The entire $10.6 million reduction in revenue is due to the successful completion of the sponsored research and development segments of the Company's license agreements with both AbbVie and Boehringer Ingelheim during 2012, as scheduled.

Research and development expenses increased to $10.3 million during the first quarter of 2013 from $9.4 million during the same pe
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
2. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
3. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
4. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
5. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
6. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
7. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
11. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... York , September 2, 2014 ... published by Transparency Market Research "Latin America Home ... Devices, Therapeutic Home Healthcare Devices, Mobility Assist Devices ... Telemedicine, Respiratory Therapy, Infusion Therapy and Unskilled Home ... Trends and Forecast, 2014 - 2020" the Latin ...
(Date:9/2/2014)... -- According to the new market research ... by Material (Metal, Glass, Plastic), by Application [GC, LC ... published by MarketsandMarkets, the Chiral Chromatography Columns Market was ... grow at a CAGR of 5.2% from 2013 to ... 90 market data tables and 15 figures spread through ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014  Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Morgan ... . , Presentation date: Tuesday September 9, 2014 ... A live webcast and 30-day archive of this presentation ... About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is ...
Breaking Medicine Technology:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey ... 2014 during Spinal Cord Injury Awareness Month featuring full band ... Chuck Ligon. Linear Automotive will be there hosting a Hot ... open at 2pm. The car show is Pre 1964 only, ... to the concert. There will be trophies for top 3 ...
(Date:9/2/2014)... September 03, 2014 Operators in the ... millions of people annually, arranging care and counsel for ... private enterprises are expected to derive $39.4 billion in ... and private income. Over the five years through 2014-15, ... rate of 6.6%, including growth of 4.1% in 2014-15. ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... new studies further confirm the health benefits of breast-feeding. ... a lower risk of ear, throat and sinus infections ... similar trend when it comes to allergies. The ... immediate newborn period," said Dr. Jennifer Wu, an obstetrician-gynecologist ... was not involved in the new studies. The ...
Breaking Medicine News(10 mins):Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... John Brumby today announced a $100 million (AUD) ... supercomputer facility to assist in discovering cures and ... brain disorders and ,flu pandemics. , In making ... at UC San Diego, Premier Brumby said the ...
... RICHMOND, Calif., June 18 Transcept,Pharmaceuticals, Inc. today ... Officer, will present at the Jefferies 2nd Annual,Healthcare ... 25, 2008 at 9:30,AM Eastern Time., The ... http://www.wsw.com/webcast/jeff26/transcept ., About Transcept Pharmaceuticals, Transcept ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... and chief executive officer, Euan S.,Thomson, Ph.D., is scheduled ... 26, 2008 at 10:15 a.m. EDT (7:15 a.m. PDT)., ... available online from the,investor relations page of the Company,s ...
... 18 The Quantum Group,Inc. (Amex: QGP ) ... for the second quarter of fiscal 2008 ended April ... 2008, the Company reported an increase,in revenues of approximately ... of fiscal year 2007. On a sequential basis compared ...
... FORT LAUDERDALE, Fla., June 18 eDiets.com,Inc. (Nasdaq: ... to bring diet,fitness and healthy lifestyle solutions to ... Information Officer effective immediately.,Bringing over 8 years of ... as the CIO and VP of IT at ...
... leader in,providing automated, molecular testing solutions, announced today ... for Human papillomavirus. Patent No.1,499 749 B1, "Human ... method for detecting the presence of HPV using ... of our collaboration with Dr. Erik,Thunnissen, a prominent ...
Cached Medicine News:Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 3Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 4Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3
... The 8600 Series Tabletop/Portable Digital ... universal tool for patient monitering. ... monitoring, the 8600 has earned ... worldwide and is recognized for ...
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Medicine Products: